As KB said yesterday the future of PLS and the industry is not with sales of spodumene. It will be more about our mid stream product or similar products. I have heard other CEO's acknowledge the need to watch developments in this space.
It would seem that, to remain relevant, other companies may need to either spend a lot of time (years) and money to develop a similar product or use PLS/Calixĺ technology.
Using PLS technology will come at a cost. The company have said they would be agreeable and consideration of 5% of that companies sales, from this use, for the first 10 years would be the fee. If I remember correctly.
That could amount to a lot of income if prices remain at or near current levels and several took up the offer.
This is another reason I and others here cheer each and every announcement regarding our progress with Calix. That is my understanding of what is going down but you better DYOR.
Good News & Bad News, page-13409
-
- There are more pages in this discussion • 33,996 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.89 |
Change
0.040(1.40%) |
Mkt cap ! $8.703B | |||
| Open | High | Low | Value | Volume |
| $2.78 | $2.89 | $2.78 | $29.90M | 10.51M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39193 | $2.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.89 | 73947 | 7 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PLS (ASX) Chart |